Higgons John Duncan 4
4 · Jounce Therapeutics, Inc. · Filed Feb 18, 2021
Insider Transaction Report
Form 4
Higgons John Duncan
Director
Transactions
- Sale
Common Stock
2021-02-16$11.78/sh−200$2,356→ 10,113 total
Footnotes (1)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2020. The Reporting Person exercised no discretion with respect to these transactions.